PDF下载 ( 2161 KB)
IgG4相关腹膜后纤维化1例报告
DOI: 10.3969/j.issn.1001-5256.2022.05.030
伦理学声明: 本例报告已获得患者知情同意。
利益冲突声明：所有作者均声明不存在利益冲突。
作者贡献声明：李朝霞负责课题设计, 资料分析, 撰写论文; 刘洋、李楠、纪竹慧参与收集数据, 修改论文; 辛桂杰负责拟定写作思路, 指导撰写文章并最后定稿。
-
-
Key words:
- Autoimmune Diseases /
- Immunoglobulin G /
- Retroperitoneal Fibrosis
-
图 1 腹部增强CT
注：a, 腹腔干周围见软组织密度影包绕, 大小约3.1 cm×3.5 cm; b, 腹腔干壁略厚, 腺形态密度未见异常。
Figure 1. Contrast-enhanced CT of the abdomen
-
[1] VASHI B, KHOSROSHAHI A. IgG4-related disease with emphasis on its gastrointestinal manifestation[J]. Gastroenterol Clin North Am, 2019, 48(2): 291-305. DOI: 10.1016/j.gtc.2019.02.008. [2] FUJIMORI N, ITO T, IGARASHI H, et al. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease[J]. World J Gastroenterol, 2013, 19(1): 35-41. DOI: 10.3748/wjg.v19.i1.35. [3] HAMANO H, KAWA S, HORIUCHI A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis[J]. N Engl J Med, 2001, 344(10): 732-738. DOI: 10.1056/NEJM200103083441005. [4] HAMANO H, KAWA S, OCHI Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis[J]. Lancet, 2002, 359(9315): 1403-1404. DOI: 10.1016/s0140-6736(02)08359-9. [5] KAMISAWA T, FUNATA N, HAYASHI Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease[J]. J Gastroenterol, 2003, 38(10): 982-984. DOI: 10.1007/s00535-003-1175-y. [6] KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699. DOI: 10.1002/art.39132. [7] URBAN ML, PALMISANO A, NICASTRO M, et al. Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach[J]. Rev Med Interne, 2015, 36(1): 15-21. DOI: 10.1016/j.revmed.2014.10.008. [8] LIU YS, ZHAO XN, WANG YY, et al. Ultrasonographic value of idiopathic retroperitoneal fibrosis[J]. Chin J Ultrasound Med, 2018, 34(12): 1105-1107. DOI: 10.3969/j.issn.1002-0101.2018.12.016.刘艳莎, 赵晓宁, 王萤萤, 等. 特发性腹膜后纤维化的超声诊断价值[J]. 中国超声医学杂志, 2018, 34(12): 1105-1107. DOI: 10.3969/j.issn.1002-0101.2018.12.016. [9] WU RY. Progress in diagnosis and treatment of retroperitoneal fibrosis(RPF)[J]. Fudan Univ J(Med Sci), 2020, 47(1): 47-52. DOI: 10.3969/j.issn.1672-8467.2020.01.009.武睿毅. 腹膜后纤维化(RPF)诊治的研究进展[J]. 复旦学报(医学版), 2020, 47(1): 47-52. DOI: 10.3969/j.issn.1672-8467.2020.01.009. [10] CHAN A, MUDHAR H, SHEN SY, et al. Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): Potential use in IgG4-RD assessment[J]. Br J Ophthalmol, 2017, 101(11): 1576-1582. DOI: 10.1136/bjophthalmol-2017-310148. [11] KOTANI S, WAKAMATSU R, ITOH A, et al. Proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) positive IgG4-related retroperitoneal fibrosis: utility of PET-CT with 18F-fluorodeoxy glucose (FDG)[J]. Intern Med, 2012, 51(7): 755-758. DOI: 10.2169/internalmedicine.51.6599. [12] BRANDT AS, KAMPER L, KUKUK S, et al. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis[J]. Urol Int, 2014, 93(3): 320-325. DOI: 10.1159/000357814. [13] van der BILT FE, HENDRIKSZ TR, van der MEIJDEN WA, et al. Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy[J]. Clin Kidney J, 2016, 9(2): 184-191. DOI: 10.1093/ckj/sfv148. [14] WALLWORK R, WALLACE Z, PERUGINO C, et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis[J]. Medicine (Baltimore), 2018, 97(42): e12631. DOI: 10.1097/MD.0000000000012631 -
下载:
本文二维码
图(2)
计量
- 文章访问数: 449
- HTML全文浏览量: 172
- PDF下载量: 47
- 被引次数: 0
